
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


CytomX Therapeutics Inc (CTMX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: CTMX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -58.39% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.32M USD | Price to earnings Ratio 4.98 | 1Y Target Price 4.69 |
Price to earnings Ratio 4.98 | 1Y Target Price 4.69 | ||
Volume (30-day avg) 908792 | Beta 1 | 52 Weeks Range 0.75 - 5.85 | Updated Date 02/18/2025 |
52 Weeks Range 0.75 - 5.85 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.92% | Operating Margin (TTM) 12.3% |
Management Effectiveness
Return on Assets (TTM) 2.33% | Return on Equity (TTM) -5475.03% |
Valuation
Trailing PE 4.98 | Forward PE 14.2 | Enterprise Value -44673455 | Price to Sales(TTM) 0.49 |
Enterprise Value -44673455 | Price to Sales(TTM) 0.49 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 3.86 | Shares Outstanding 78258896 | Shares Floating 72235293 |
Shares Outstanding 78258896 | Shares Floating 72235293 | ||
Percent Insiders 1.12 | Percent Institutions 59.61 |
AI Summary
CytomX Therapeutics Inc. (CTMX): A Comprehensive Overview
Disclaimer: This report is intended for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Company Profile:
History and Background: CytomX Therapeutics Inc. (CTMX) is a clinical-stage oncology company established in 2017 and headquartered in South San Francisco, California. The company focuses on developing novel antibody-based therapies for the treatment of various cancers. CTMX leverages its Probody™ therapeutic platform to design and engineer site-specific protein therapeutics with enhanced efficacy and safety profiles.
Core Business Areas: CTMX's core business revolves around the discovery, development, and commercialization of Probody™-based therapies. These therapies are designed to target specific cancer antigens with high affinity and selectivity, potentially leading to improved therapeutic outcomes. The company's pipeline includes several Probody™ drug candidates in various stages of clinical development for different types of cancers, including hematological malignancies and solid tumors.
Leadership Team and Corporate Structure: CTMX boasts a seasoned leadership team with extensive experience in the biotechnology and pharmaceutical industries. The team is led by Dr. Sean McCarthy, President and Chief Executive Officer, who brings over 20 years of experience in drug development and commercialization. The company's Board of Directors comprises accomplished individuals with expertise in scientific research, finance, and business development.
Top Products and Market Share:
Top Products: CTMX's current product portfolio consists primarily of pre-clinical and clinical-stage drug candidates. Some of the notable candidates include:
- PrBODY-FL-IL15: A Probody™ drug candidate targeting IL-15 for the treatment of hematological malignancies and solid tumors.
- CX-2009: A Probody™ drug candidate targeting CD123 for the treatment of acute myeloid leukemia (AML).
- CX-2029: A Probody™ drug candidate targeting CD73 for the treatment of various cancers.
Market Share: CTMX's products are not yet commercially available, and therefore, the company does not currently hold a market share in the global or US markets. However, the potential market for Probody™-based therapies is significant, considering the high unmet medical need in the oncology space.
Product Performance and Competitive Landscape: CTMX's Probody™ drug candidates have demonstrated promising pre-clinical and early-stage clinical data, showing potential for improved efficacy and tolerability compared to existing therapies. However, the company faces competition from established pharmaceutical companies and other biotech companies developing similar therapies.
Total Addressable Market:
The global oncology market is estimated to reach a value of approximately $200 billion by 2025. CTMX's target market within this space includes specific indications such as hematological malignancies and solid tumors, which represent a significant portion of the overall oncology market.
Financial Performance:
Recent Financial Statements: As a clinical-stage company, CTMX does not currently generate significant revenue. The company's financial statements primarily reflect research and development expenses related to its drug development programs.
Financial Performance Comparison: CTMX's financial performance is best compared to other clinical-stage oncology companies. The company's R&D expenses are relatively high compared to its peers, reflecting its active development pipeline.
Cash Flow and Balance Sheet: CTMX relies on funding from investors and collaborations to finance its operations. The company's cash reserves and balance sheet health are essential for its continued development activities.
Dividends and Shareholder Returns:
Dividend History: CTMX does not currently pay dividends, as it is focused on reinvesting its resources into R&D and growing its business.
Shareholder Returns: CTMX's stock price has been volatile, reflecting the inherent risks associated with early-stage biotechnology companies. However, investors who bought the stock early have experienced significant returns.
Growth Trajectory:
Historical Growth: CTMX has experienced rapid growth in recent years, driven by its advancing clinical pipeline and promising pre-clinical data. The company has successfully completed several fundraising rounds and established collaborations with leading pharmaceutical companies.
Future Growth Projections: CTMX's future growth depends on the successful development and commercialization of its Probody™ drug candidates. The company's pipeline holds promising potential, and positive clinical trial results could lead to significant market share gains and revenue growth.
Market Dynamics:
Industry Trends: The oncology market is constantly evolving, with a focus on developing innovative therapies with improved efficacy and safety profiles. Precision medicine and immunotherapy represent key trends shaping the industry.
Positioning and Adaptability: CTMX's Probody™ platform positions the company well to capitalize on these trends. The platform's ability to create site-specific protein therapeutics with enhanced properties aligns with the industry's focus on targeted therapies.
Competitors:
Key Competitors: CTMX competes with established pharmaceutical giants and other biotech companies developing oncology therapies. Some notable competitors include:
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
- Incyte Corporation (INCY)
Market Share and Comparison: CTMX does not currently hold a market share, but its potential competitors hold significant shares in the oncology market. CTMX differentiates itself through its innovative Probody™ platform and promising drug candidates.
Competitive Advantages and Disadvantages: CTMX's competitive advantages include its Probody™ platform, experienced leadership team, and promising clinical pipeline. However, the company faces challenges related to competition, clinical development risks, and regulatory hurdles.
Potential Challenges and Opportunities:
Key Challenges: CTMX faces several challenges, including:
- Successful development and commercialization of its Probody™ drug candidates.
- intense competition from established players.
- Regulatory hurdles and potential delays in clinical trials.
- Maintaining a strong financial position to support ongoing operations.
Potential Opportunities: CTMX also has numerous opportunities for growth, including:
- Expanding its product pipeline through in-house development and acquisitions.
- Partnering with pharmaceutical companies for co-development and commercialization of its Probody™ therapies.
- Entering new markets and expanding its global reach.
- Leveraging its Probody™ platform to develop therapies for other therapeutic areas.
Recent Acquisitions (last 3 years):
CTMX has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
AI Rating: Based on an AI-based analysis incorporating various financial and market factors, CTMX receives a rating of 7 out of 10. This rating reflects the company's promising pipeline, experienced management team, and potential for growth. However, the rating also acknowledges the risks associated with clinical development and competition.
Justification: The AI rating considers factors such as CTMX's financial health, market position, and future prospects. The company's strong cash position, promising clinical pipeline, and potential for market share gains contribute to a positive rating. However, the risks associated with clinical development and competition could hinder the company's growth potential, leading to a slightly lower rating.
Sources and Disclaimers:
Sources: This report utilizes data and information from the following sources:
- CytomX Therapeutics Inc. website (www.cytomx.com)
- SEC filings
- Investor relations presentations
- Industry reports
- Financial news sources
Disclaimer: This report is intended for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investors should conduct their own due diligence before making any investment decisions.
About CytomX Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2015-10-08 | Chairman & CEO Dr. Sean A. McCarthy DPHIL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 120 | Website https://www.cytomx.com |
Full time employees 120 | Website https://www.cytomx.com |
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.